Appeal No. 2005-0027
Application No. 09/777,874
26. A method for reducing food consumption comprising administering to a
subject in need thereof, an effective amount of the composition of Claim 11.
27. A method for reducing body weight comprising administering to a subject in
need thereof, an effective amount of the composition of Claim 11.
28. A method for reducing serum triglycerides comprising administering to a
subject in need thereof, an effective amount of the composition of Claim 11.
29. A method for treating hypertriglyceridaemia comprising administering to a
subject in need thereof, an effective amount of the composition of Claim 11.
30. A method for treating hypercholesterolaemia comprising administering to a
subject in need thereof, an effective amount of the composition of Claim 11.
The prior art references cited by the examiner are:
Wiegand 3,810,994 May 1974
Cavazza 4,268,524 May 1981
Stracher et al (Stracher) 5,008,288 April 1991
Burtle et al (Burtle) 5,030,657 July 1991
Moffett et al (Moffett) 5,536,516 July 1996
Hastings et al (Hastings) 5,626,849 May 1997
Wiener et al. (Weiner), “Liposomes as a Drug Delivery System,” Drug Development and
Industrial Pharmacy, Vol. 15, No. 10, pp. 1523-1556 (1989)
Grounds of Rejection
1. Claims 11-18, 20-27 and 311 stand rejected under 35 U.S.C. §103(a), as
1 In the final rejection, page 4 (Paper No. 8) claims 11-18 and 20-31 were
rejected over Hastings in view of Weigand or Burtle. In the Answer, the examiner
removed the rejection from claims 28-30. Answer, page 2.
2
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 Next
Last modified: November 3, 2007